FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

22384211000001101: Rivastigmine 13.3mg/24hours transdermal patches 30 patch (product)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 29-May 2013. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
73836801000001118 Rivastigmine 13.3mg/24hours transdermal patches 30 patch (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
73836901000001112 Rivastigmine 13.3mg/24hours transdermal patches 30 patch en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

6 descendants. Search Descendants:

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Rivastigmine 13.3mg/24hours transdermal patches 30 patch Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Rivastigmine 13.3mg/24hours transdermal patches 30 patch Is a Virtual medicinal product pack true Inferred relationship Existential restriction modifier
Rivastigmine 13.3mg/24hours transdermal patches 30 patch Has VMP Rivastigmine 13.3mg/24hours transdermal patches true Inferred relationship Existential restriction modifier
Rivastigmine 13.3mg/24hours transdermal patches 30 patch VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
Rivastigmine 13.3mg/24hours transdermal patches 30 patch VMP non-availability indicator Available true Inferred relationship Existential restriction modifier
Rivastigmine 13.3mg/24hours transdermal patches 30 patch Has specific active ingredient Rivastigmine true Inferred relationship Existential restriction modifier
Rivastigmine 13.3mg/24hours transdermal patches 30 patch Has dispensed dose form Prolonged-release transdermal patch true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Almuriva 13.3mg/24hours transdermal patches (Sandoz Ltd) 30 patch Is a True Rivastigmine 13.3mg/24hours transdermal patches 30 patch Inferred relationship Existential restriction modifier
Alzest 13.3mg/24hours transdermal patches (Dr Reddy's Laboratories (UK) Ltd) 30 patch Is a True Rivastigmine 13.3mg/24hours transdermal patches 30 patch Inferred relationship Existential restriction modifier
Exelon 13.3mg/24hours transdermal patches (CST Pharma Ltd) 30 patch Is a True Rivastigmine 13.3mg/24hours transdermal patches 30 patch Inferred relationship Existential restriction modifier
Exelon 13.3 mg/24hours transdermal patches (Novartis Pharmaceuticals UK Ltd) 30 patch Is a True Rivastigmine 13.3mg/24hours transdermal patches 30 patch Inferred relationship Existential restriction modifier
Erastig 13.3mg/24hours transdermal patches (Teva UK Ltd) 30 patch Is a True Rivastigmine 13.3mg/24hours transdermal patches 30 patch Inferred relationship Existential restriction modifier
Rivastigmine 13.3mg/24hours transdermal patches (A A H Pharmaceuticals Ltd) 30 patch Is a False Rivastigmine 13.3mg/24hours transdermal patches 30 patch Inferred relationship Existential restriction modifier
Voleze 13.3mg/24hours transdermal patches (Focus Pharmaceuticals Ltd) 30 patch Is a True Rivastigmine 13.3mg/24hours transdermal patches 30 patch Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start